Abstract: Disclosed are systems, methods, computer program products, and other implementations, including a method for signal detection is disclosed that includes obtaining samples of observation data comprising a signal component produced by a source object, and a noise component, and generating based on at least one of the samples of the observation data, processed by a machine learning template derivation system, a filtering template to separate the signal component from the noise component, with the machine learning template derivation system including one or more trainable layers, and with at least one layer of the one or more trainable layers implementing a respective one of one or more iterations of an unrolled optimization process to determine optimized template parameters for the filtering template. The method further includes applying the filtering template to one or more of the samples of the observation data to obtain the signal component of the observation data.

Abstract: The present disclosure provides a Lipid-Based Enhancement Agent being a compound of Formula (I), (II), (III), or (IV): or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Based Enhancement Agents and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.

Abstract: Embodiments described herein provide a diffusion-based framework that is trained on a dataset with limited text labels, to generate a distribution of data samples in the dataset given a specific text description label. Specifically, firstly, unlabeled data is used to train the diffusion model to generate a data distribution of data samples given a specific text description label. Then text-labeled data samples are used to finetune the diffusion model to generate data distribution given a specific text description label, thus enhancing controllability of training.

Abstract: The disclosure relates to isolated oligonucleotides comprising duplex regions targeting angiopoietin-like 3 (ANGPTL-3), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating ANGPTL-3.

Abstract: The disclosure relates to isolated oligonucleotides comprising duplex regions targeting Proprotein convertase subtilisin kexin 9 (PCSK9), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating PCSK9.

Abstract: The present disclosure provides a Lipid-Based Lipid Agent being a compound of Formula (I), (II), (III), or (IV): or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Based Lipid Agents and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.

Abstract: A method for determining an effect relationship between various substances and cells, including: providing a first droplet, a second droplet, a third droplet, and a microwell array chip, a plurality of microwell combinations being provided on the microwell array chip, fusing the first droplet and the second droplet on the microwell array chip, and performing cell culture; adding the third droplet into the microwell array chip, and fusing the third droplet with the first fused droplet subjected to the cell culture, to obtain a second fused droplet, performing demulsification, library construction, and sequencing, and determining an effect relationship between various substances and cells on the basis of the sequencing result.

Abstract: This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human apolipoprotein C3 (ApoC3) mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating ApoC3 gene expression.

Abstract: This disclosure relates to isolated oligonucleotides comprising duplex regions targeting hepatitis B virus (HBV) mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating HBV gene and surface antigen expression.

Abstract: This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human complement C3 mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating C3 gene expression.

Abstract: A continuous-variable quantum key distribution (CV-QKD) method and system is provided. The CV-QKD method includes: step 1: transmitting a quantum signal and a local oscillation signal synchronously based on time and polarization multiplexing, and performing detection to obtain detection data; and step 2: compensating for the detection data based on a phase compensation algorithm and public data. In this way, a phase can be compensated accurately in channel fading, so as to improve performance of the CV-QKD system.

Abstract: This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human CFB mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating CFB gene expression.

Abstract: An electrolyte solution and an all-vanadium redox flow battery are disclosed. The electrolyte solution includes: a positive electrode electrolyte solution and a negative electrode electrolyte solution, the positive electrode electrolyte solution and the negative electrode electrolyte solution include chloride ions, sulfate ions and vanadium ions; both the positive electrode electrolyte solution and the negative electrode electrolyte solution satisfy: 2.9?[c(Cl?)+c(SO42?)]/c(Vn+)?3.6; the c(Cl?) represents a concentration of the chloride ions, the c(SO42?) represents a concentration of the sulfate ions, and the c(Vn+) represents a concentration of the vanadium ions. When Cl?, SO42? and Vn+ in the electrolyte solution meet the appropriate concentration relationship, the Cl2 production rate can be greatly reduced, thereby reducing the corrosion of battery materials.

Abstract: The present disclosure provides optimized isolated oligonucleotides comprising specific combination of 2?-ribose derivatives or substitutions, to enhance stability and potency of the same for delivery and use as therapeutic agents.

Abstract: This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human complement C3 mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating C3 gene expression.

Abstract: The disclosure relates to isolated oligonucleotides comprising duplex regions targeting angiopoietin-like 3 (AGT), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating AGT.

Abstract: The disclosure relates to isolated oligonucleotides comprising duplex regions targeting hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating HSD17B13.

Abstract: Oligonucleotides are provided herein that inhibit MAPT gene expression, including oligonucleotides conjugated to a targeting ligand (e.g., lipid moiety). Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders, and/or conditions associated with MAPT gene expression.

Abstract: Oligonucleotides (e.g., RNAi oligonucleotides) are provided herein that inhibit SNCA gene expression, including oligonucleotides conjugated to a targeting ligand (e.g., GalNAC moiety or lipid moiety). Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders, and/or conditions associated with SNCA gene expression.

Abstract: The disclosure relates to isolated oligonucleotides comprising duplex regions targeting angiopoietin-like 3 (ANGPTL-3), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating ANGPTL-3.